Contribute Try STAT+ Today

Editors note: A livestream of the conversation will be embedded below at 1 p.m. ET.

Every week STAT+ subscribers get access to exclusive content with biotech, pharma, and health tech leaders. This week, STAT general assignment reporter and associate editorial director of events Nicholas St. Fleur will be joined by STAT science writer Megan Molteni. They will be discussing Molteni’s recent report on Intellia Therapeutics’ positive early data on in vivo CRISPR therapy. They will explore the details of this milestone, what it means for patients, and of course be taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment